The Martinsried-based company leon-nanodrugs, which specializes in nano-encapsulation systems, has completed a Series D financing round to expand its portfolio and drive forward the production of cell and gene therapies.
leon-nanodrugs GmbH, based at the IZB in Martinsried, develops and commercializes its innovative technology for the encapsulation of genetic material and other active ingredients in nano drug carriers such as lipid nanoparticles (LNPs).
With its technology, the company aims to make modern drugs such as prophylactic mRNA vaccines as well as individual therapies such as personalized cancer vaccines available to patients quickly and on a large scale.
The devices from LEON's product platform are based on the innovative FR-JET technology, which enables an enormous increase in efficiency in the production of the LNP-packaged active ingredient. The GMP-compliant, aseptic devices are suitable for both study scale and commercial production.
In addition to its own device platform, LEON offers in-house laboratory capacities for process development at the IZB.
“I am very pleased that we have completed this financing in the planned amount. The new funds will be used to augment the product portfolio. Our portfolio of leading equipment is designed to serve the Cell & Gene Therapy industry, enabling highly economic GMP manufacturing of small and individualized batches of nanoencapsulated Cell & Gene Therapies. Together with the financing, this puts us in a good position to select the best possible strategic partner to bring those products to the market”, commented Christian Nafe, Managing Director & CFO of LEON.
New lead investor LBBW Venture Capital closed the round together with new investors and existing shareholders like Albany Private Equity Holdings Pty Ltd., CD-Venture GmbH, Eckenstein-Geigy-Stiftung, Signet Healthcare Partners, TVM Life Science Innovation I L.P., and others.